Saralasin

Saralasin ([Sar1], [Ala8]-Ang II) is a partial agonist of angiotensin II receptors, though it is commonly mistaken as a competitive antagonist.

Designed for biological research and industrial applications, not intended for individual clinical or medical purposes.
Saralasin(CAS 34273-10-4)

CAT No: 10-101-304

CAS No:34273-10-4

Synonyms/Alias:Saralasin;34273-10-4;Saralasina;Saralasine;Saralasinum;Sar-Arg-Val-Tyr-Val-His-Pro-Ala;Saralasinum [INN-Latin];Saralasin [INN:BAN];Saralasine [INN-French];Saralasina [INN-Spanish];DTXSID2046549;(Sar1,Val5,Ala8)-Angiotensin II;CHEMBL938;H2AFV2HE66;1-Sar-8-Ala-angiotensin II;(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[2-(methylamino)acetyl]amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;DTXCID0026549;Angiotensin II, 1-(N-methylglycine)-5-L-valine-8-L-alanine-;(Sar(1),Ala(8))ANGII;(1-(N-Methylglycin) 5-L-valin, 8-L-alanin)angiotensin II;Saralasine (INN-French);Saralasinum (INN-Latin);Saralasina (INN-Spanish);N-(1-(N-(N-(N-(N-(N2-(N-methylglycly)-L-arginyl)-L-valyl)-L-tyrosyl)-L-valyl)-L-histidyl)-L-prolyl)-L-alanine;UNII-H2AFV2HE66;1 Sar 8 Ala Angiotensin II;1-Sar-8-Ala Angiotensin II;Angiotensin II, 1-Sar-8-Ala;(Sar1,Val5,Ala8)Angiotensin II;NCGC00166135-01;(2S)-2-(((2S)-1-((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-5-(diaminomethylideneamino)-2-((2-(methylamino)acetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid;angiotensin II, Sar(1)-Ala(8)-;1 Sarcosine 8 Alanine Angiotensin II;1-Sarcosine-8-Alanine Angiotensin II;Angiotensin II, 1-Sarcosine-8-Alanine;angiotensin II, sarcosyl(1)-alanine(8)-;SARALASIN [INN];SARALASIN [MI];SCHEMBL23;CHEBI:135894;2-((1-(2-((2-((2-((2-((5-(diaminomethylideneamino)-2-((2-methylaminoacetyl)amino)pentanoyl)amino)-3-methylbutanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-3-methylbutanoyl)amino)-3-(3H-imidazol-4-yl)propanoyl)pyrrolidine-2-carbonyl)amino)propanoic acid;2-[[1-[2-[[2-[[2-[[2-[[5-(diaminomethylideneamino)-2-[(2-methylaminoacetyl)amino]pentanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-3-(3H-imidazol-4-yl)propanoyl]pyrrolidine-2-carbonyl]amino]propanoic acid;HY-P0205;Tox21_112332;BDBM50009338;BDBM50229504;AKOS024456428;DB06763;NCGC00167316-01;FS108389;CAS-34273-10-4;CS-0021297;NS00073478;Sar-Arg-Val-Tyr-Val-His-Pro-Ala (sarlasin);[Sar1-Arg2-Val3-Tyr4-Val5-His6-Pro7-Ala8];Q410298;(Sar 1,Val5,Ala8)-Angiotensin II trifluoroacetate salt;ANGIOTENSIN II, 1-SARCOSINE-5-L-VALINE-8-L-ALANINE-;Saralasin;Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH trifluoroacetate salt;L-ALANINE, N-METHYLGLYCYL-L-ARGINYL-L-VALYL-L-TYROSYL-L-VALYL-L-HISTIDYL-L-PROLYL-;(S)-2-((S)-1-((6S,9S,12S,15S,18S)-18-((1H-imidazol-4-yl)methyl)-6-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-9,15-diisopropyl-4,7,10,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecane)pyrrolidine-2-carboxamido)propanoic acid;(S)-2-((S)-1-((S)-2-((S)-2-((S)-2-((S)-2-((S)-5-(diaminomethyleneamino)-2-(2-(methylamino)acetamido)pentanamido)-3-methylbutanamido)-3-(4-hydroxyphenyl)propanamido)-3-methylbutanamido)-3-(1H-imidazol-5-yl)propanoyl)pyrrolidine-5-carboxamido)propanoic acid;60173-70-8;

Custom Peptide Synthesis
cGMP Peptide
  • Registration of APIs
  • CMC information required for an IND
  • IND and NDA support
  • Drug master files (DMF) filing
M.F/Formula
C42H65N13O10
M.W/Mr.
912
Sequence
One Letter Code:GRVYVHPA
Three Letter Code:H-Sar-Arg-Val-Tyr-Val-His-Pro-Ala-OH
Purity
≥97% (HPLC)
Activity
Agonist
Target
Angiotensin II Receptors
Source#
Synthetic
Long-term Storage Conditions
1 mg/ml in water
Shipping Condition
+20°C (International: -20°C)
InChI
InChI=1S/C42H65N13O10/c1-22(2)33(53-35(58)28(50-32(57)20-45-6)9-7-15-47-42(43)44)38(61)51-29(17-25-11-13-27(56)14-12-25)36(59)54-34(23(3)4)39(62)52-30(18-26-19-46-21-48-26)40(63)55-16-8-10-31(55)37(60)49-24(5)41(64)65/h11-14,19,21-24,28-31,33-34,45,56H,7-10,15-18,20H2,1-6H3,(H,46,48)(H,49,60)(H,50,57)(H,51,61)(H,52,62)(H,53,58)(H,54,59)(H,64,65)(H4,43,44,47)/t24-,28-,29-,30-,31-,33-,34-/m0/s1
InChI Key
PFGWGEPQIUAZME-NXSMLHPHSA-N
Canonical SMILES
CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(C(C)C)C(=O)NC(CC2=CN=CN2)C(=O)N3CCCC3C(=O)NC(C)C(=O)O)NC(=O)C(CCCN=C(N)N)NC(=O)CNC
Isomeric SMILES
C[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC

Useful Tools

Peptide Calculator

Abbreviation List

Peptide Glossary

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Featured Services
Peptide Analysis ServicesEpitope Mapping ServicesPeptide Synthesis ServicescGMP Peptide ServicePeptide Nucleic Acids SynthesisPeptide Modification ServicesCustom Conjugation ServicePeptide CDMO
Hot Products
About us

Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.

From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.

Our Customers